Putra Andi Darma, Winarto Hariyono, Prijanti Ani Retno, Pakasi Trevino Aristarkus, Gandamihardja Supriadi, Wirasugianto Jourdan, Syariatin Lasmini
Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Indonesia, Central Jakarta 10430, Indonesia.
Division of Gynecology-Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Central Jakarta 10430, Indonesia.
Curr Issues Mol Biol. 2025 May 16;47(5):365. doi: 10.3390/cimb47050365.
Cervical cancer is the fourth most prevalent cancer among women globally. Protein concentrations of Large Tumor Suppressor Kinase-1 (LATS1) and Nuclear Factor Kappa-B (NF-κB) have been identified as prospective biomarkers of radioresistance in cervical cancer. This preliminary study aimed to investigate the effectiveness of LATS1 and NF-κB levels as a biomarker for radioresistance and evaluate their response to radiation in cervical cancer patients. A comprehensive cross-sectional study was conducted involving 114 subjects diagnosed with advanced stages cervical cancer (stage IIIB and IVA) who underwent definitive radiotherapy. The concentrations of LATS1 and NF-κB were measured using ELISA from biopsy samples taken prior to the initiation of radiotherapy. This study's finding included 114 subjects, with a median age of 53 years. A total of 85 (74.5%) subjects had stage IIIB, while 29 (25.4%) subjects had stage IVA. The cut-offs for LATS1 and NF-κB were 0.02765 ng/mg and 192.42 pg/mg, respectively. Subjects with a higher expression of LATS1 were found to be unresponsive to radiation therapy ( ≤ 0.001; AUC = 32.7%), and subjects with a lower expression of NF-κB were found to be unresponsive to radiation therapy ( = 0.009; AUC = 61%). This study suggests that elevated LATS1 expression may inversely predict radioresistance, while NF-κB expression shows a weak correlation with resistance to radiation therapy.
宫颈癌是全球女性中第四大常见癌症。大肿瘤抑制激酶-1（LATS1）和核因子κB（NF-κB）的蛋白浓度已被确定为宫颈癌放射抗性的潜在生物标志物。这项初步研究旨在调查LATS1和NF-κB水平作为放射抗性生物标志物的有效性，并评估它们在宫颈癌患者中对放疗的反应。进行了一项全面的横断面研究，纳入了114名被诊断为晚期宫颈癌（IIIB期和IVA期）并接受根治性放疗的受试者。在放疗开始前，使用酶联免疫吸附测定法（ELISA）从活检样本中测量LATS1和NF-κB的浓度。该研究的结果包括114名受试者，中位年龄为53岁。共有85名（74.5%）受试者为IIIB期，而29名（25.4%）受试者为IVA期。LATS1和NF-κB的截断值分别为0.02765 ng/mg和192.42 pg/mg。发现LATS1表达较高的受试者对放疗无反应（≤0.001；AUC = 32.7%），而NF-κB表达较低的受试者对放疗无反应（= 0.009；AUC = 61%）。这项研究表明，LATS1表达升高可能反向预测放射抗性，而NF-κB表达与放疗抗性的相关性较弱。
